-
[Interview] Novel immunotherapy nelmastobart shows promise in MSS colorectal cancer: early trial data
28 Feb 2025 10:38 GMT
… the Department of Medical Oncology and … monotherapy, and although Xeloda (ingredient: capecitabine) … with multinational pharmaceutical companies.
For this new trial, nelmastobart … drugs that surpass oxaliplatin or irinotecan in MSS colorectal cancer treatment …
-
Breaking Down the FDA Labeling Update of Xeloda and 5-FU in Cancer Care
10 Feb 2025 22:25 GMT
… to treatment.
Brooks is an associate professor of medicine and … deficiency before starting treatment with fluorouracil or Xeloda?
The best … do chemotherapy treatment with 5-FU or Xeloda, as soon … doctors, as advised on the FDA drug labels for 5-FU and Xeloda …
-
An Expert Breaks Down What DPD Is and Labeling Updates From The FDA
10 Feb 2025 22:25 GMT
… Drug Administration (FDA), the labeling for Xeloda (capecitabine) and fluorouracil (5-FU) chemotherapy treatment … , at Dartmouth Geisel School of Medicine, in Lebanon, New Hampshire.
… discussion with your doctor and understanding that your doctor may not be …
-
FDA Approves T-DXd in HR+, HER2-Low/Ultralow Breast Cancer
28 Jan 2025 00:55 GMT
… The FDA has approved trastuzumab deruxtecan for the treatment of … FASCO, professor, department of medicine, division of hematology/ … on the DESTINY-Breast04 trial (NCT03734029).3 Notably, … which consisted of capecitabine (Xeloda; 59.8%), nab-paclitaxel …
-
Safety announcement: FDA highlights importance of DPD deficiency discussions with patients prior to capecitabine or 5FU treatment
24 Jan 2025 23:18 GMT
… U.S. Food and Drug Administration (FDA) is providing this communication … inform patients prior to treatment about the potential for … reactions.
Project Renewal
The FDA Oncology Center of Excellence, … as in Xeloda. The product labeling of both drugs state:
…
-
Metronomic Capecitabine With an Aromatase Inhibitor Demonstrates Safety, Efficacy in Treatment of HR+, HER2– Metastatic Breast Cancer
15 Jan 2025 17:58 GMT
Metronomic capecitabine (Xeloda; Genetech) plus an … , controlled phase 3 MECCA trial (NCT02767661).1
Endocrine therapy … Docefrez; Sun Pharmaceutical Industries Europe B.V.) for treatment of MBC … al. US Food and Drug Administration approval overview in …
-
ctDNA Positivity More Frequent Less Than 6 Months from Treatment in TNBC
20 Dec 2024 22:55 GMT
… the end of treatment.
The ZEST trial was considered the … ). Prior therapies included capecitabine (Xeloda; 61.1%; 31.8%), … the end of definitive treatment (EODT), 5.2% … ) pathological outcome from neoadjuvant treatment (non-pathologic complete response, …
-
Biomarker-Guided Treatment Approaches Transform Lung and GI Cancer Management
13 Dec 2024 20:00 GMT
… and Medical Oncology, Mayo Clinic; co-leader, Advanced Clinical Trials … many treatment options, and there’s not a clinical trial … . However, only 2 drugs are FDA approved in the second … addition of zolbetuximab to capecitabine [Xeloda] and oxaliplatin [CAPOX] …
-
Zolbetuximab Plus Chemotherapy Offers Survival Benefits in Treatment-Naive HER2– Gastric/GEJ Cancer
12 Nov 2024 20:15 GMT
… trials. These data were published in the New England Journal of Medicine … oral capecitabine (Xeloda) 1000 mg… trial that enrolled adult patients with CLDN18.2-positive, HER2-negative, treatment … fda.gov/drugs/;resources-information-approved-drugs/fda …
-
Camber Pharmaceuticals Launches Generic Xeloda®
12 Nov 2024 16:21 GMT
Camber Pharmaceuticals is excited to announce the addition of Capecitabine Tablets, USP, to our product portfolio. Capecitabine is a nucleoside metabolic inhibitor indicated for the treatment of several cancers, including:
Colorectal Cancer
Breast Cancer
…